MedPath

Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Procedure: PET Scan
Registration Number
NCT02795780
Lead Sponsor
Avid Radiopharmaceuticals
Brief Summary

This study will evaluate longitudinal change of tau deposition as measured by flortaucipir F 18 uptake over time.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
79
Inclusion Criteria
  • Confirmatory cohort subjects who completed the 18F-AV-1451-A05 (NCT02016560) study
Exclusion Criteria
  • Current clinically significant cardiovascular disease, ECG abnormalities, risk factors for Torsades de Pointes (TdP), or are taking drugs known to cause QT prolongation
  • Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
  • Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception
  • Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session
  • Have received or participated in a trial with investigational medications in the past 30 days

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Follow-up Flortaucipir PET ScanPET Scan-
Follow-up Flortaucipir PET ScanFlortaucipir F18-
Primary Outcome Measures
NameTimeMethod
Change in Tau Deposition Over Time by Diagnostic Group and Amyloid Status18 months

Change in flortaucipir standardized uptake value ratio (SUVr) over 18 months. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain. A positive change in SUVr represents an increase in tau deposition in the brain. Change = 18 month SUVr - baseline SUVr obtained in Study A05.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (22)

Institute for Brain Aging and Dementia, UC Irvine

🇺🇸

Irvine, California, United States

California Medical Clinic for Headache

🇺🇸

Santa Monica, California, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Imaging Endpoints

🇺🇸

Scottsdale, Arizona, United States

Banner Alzheimer's Institute

🇺🇸

Phoenix, Arizona, United States

Mayo Clinic Arizona

🇺🇸

Scottsdale, Arizona, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Las Vegas Radiology

🇺🇸

Las Vegas, Nevada, United States

Meridien Research

🇺🇸

Saint Petersburg, Florida, United States

Premiere Research Institute

🇺🇸

West Palm Beach, Florida, United States

Boston University School of Medicine

🇺🇸

Boston, Massachusetts, United States

New York University Center for Brain Health

🇺🇸

New York, New York, United States

21st Century Oncology

🇺🇸

Newport Beach, California, United States

Neuropsychiatric Research Center of Southwest Florida

🇺🇸

Fort Myers, Florida, United States

Banner Sun Health Research Institute

🇺🇸

Sun City, Arizona, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Butler Hospital

🇺🇸

Providence, Rhode Island, United States

Alzheimer's Disease Center, UC Davis

🇺🇸

Sacramento, California, United States

Compass Research, LLC

🇺🇸

Orlando, Florida, United States

University of South Florida Health Byrd Alzheimer's Institute

🇺🇸

Tampa, Florida, United States

Rhode Island Hospital

🇺🇸

Providence, Rhode Island, United States

© Copyright 2025. All Rights Reserved by MedPath